Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Tegze, Bálint ^a   Szállási, Zoltán ^b,c   Haltrich, Irén ^d   Pénzváltó, Zsófia ^a   Tóth, Zsuzsa ^d   Likó, István ^e   Gyorffy, Balázs ^f,g  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e GEDEON RICHTER LTD   (Hungary)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABCB1 GENE; ABCG2 GENE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SUBPOPULATION; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; CROSS RESISTANCE; CYTOGENETICS; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IC 50; KARYOTYPE; MICROTUBULE ASSEMBLY; MVP GENE; ONCOGENE; PGP GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ANALYSIS; TOP2A GENE; ASTRONOMY; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENETICS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EVOLUTION, CHEMICAL; FEMALE; HUMANS; PACLITAXEL;

EID: 84856413433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030804     Document Type: Article

References (36)

1. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712.
2. Wang HM, Mao Y, Zhou N, Hu T, Hsieh TS, et al. (2001) ATP-bound topoisomerase II as a target for antitumor drugs. Journal of Biological Chemistry 276: 15990-15995.
3. Lehne G, Morkrid L, den Boer M, Rugstad HE, (2000) Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). International Journal of Clinical Pharmacology and Therapeutics 38: 187-195.
4. Kartner N, Riordan JR, Ling V, (1983) Cell-Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian-Cell Lines. Science 221: 1285-1288.
5. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, et al. (2005) Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24: 7542-7551.
6. Dalton WS, Scheper RJ, (1999) Lung resistance-related protein: Determining its role in multidrug resistance. Journal of the National Cancer Institute 91: 1604-1605.
7. Renes J, de Vries EGE, Jansen PLM, Muller M, (2000) The (patho)physiological functions of the MRP family. Drug Resistance Updates 3: 289-302.
8. Borst P, Evers R, Kool M, Wijnholds J, (2000) A family of drug transporters: The multidrug resistance-associated proteins. Journal of the National Cancer Institute 92: 1295-1302.
9. Munkacsy G, Abdul-Ghani R, Mihaly Z, Tegze B, Tchernitsa O, et al. (2010) PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer. Br J Cancer 102: 361-368.
10. Doroshow JH, (1986) Prevention of Doxorubicin-Induced Killing of Mcf-7 Human-Breast Cancer-Cells by Oxygen Radical Scavengers and Iron Chelating-Agents. Biochemical and Biophysical Research Communications 135: 330-335.
11. Lage H, Helmbach H, Dietel M, Schadendorf D, (2000) Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. British Journal of Cancer 82: 488-491.
12. Eijdems EWHM, Dehaas M, Timmerman AJ, Vanderschans GP, Kamst E, et al. (1995) Reduced Topoisomerase-Ii Activity in Multidrug-Resistant Human Nonsmall Cell Lung-Cancer Cell-Lines. British Journal of Cancer 71: 40-47.
13. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218.
14. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, et al. (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398.
15. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, et al. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106.
16. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, et al. (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305.
17. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293.
18. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793.
19. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, et al. (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102: 8315-8320.
20. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, et al. (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153.
21. Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, et al. (2011) Multifactorial Approach to Predicting Resistance to Anthracyclines. J Clin Oncol.
22. Ein-Dor L, Zuk O, Domany E, (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103: 5923-5928.
23. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15: 68-74.
24. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12: 1294-1300.
25. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2011) Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med 17: 135.
26. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, et al. (2010) Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121: 301-309.
27. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, et al. (2011) Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71: 1081-1091.
28. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
29. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
30. Gyorffy B, Gyorffy A, Tulassay Z, (2005) [The problem of multiple testing and solutions for genome-wide studies]. Orv Hetil 146: 559-563.
31. Shannon CE, (1997) The mathematical theory of communication, 1963. MD Comput 14: 306-317.
32. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38: 468-473.
33. Saad ED, Katz A, Buyse M, (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28: 1958-1962.
34. Marusyk A, Polyak K, (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805: 105-117.
35. Gerlinger M, Swanton C, (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103: 1139-1143.
36. Andre F, Berrada N, Desmedt C, (2010) Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol 22: 547-551.